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Many reports conclude nanoparticle (NP) brain entry based on bulk brain analysis. Bulk brain includes
blood, cerebrospinal fluid and blood vessels within the brain contributing to the blood–brain and
blood–cerebrospinal fluid barriers. Considering the brain as neurons, glia and their extracellular space
(brain parenchyma), most studies did not show brain parenchymal NP entry. Blood–brain and blood–
cerebrospinal fluid barriers anatomy and function are reviewed. Methods demonstrating brain parenchy-
mal NP entry are presented. Results demonstrating bulk brain versus brain parenchymal entry are clas-
sified. Studies are reviewed, critiqued and classified to illustrate results demonstrating bulk brain versus
parenchymal entry. Brain, blood and peripheral organ NP timecourses are compared and related to brain
parenchymal entry evidence suggesting brain NP timecourse informs about brain parenchymal entry.
First draft submitted: 26 April 2019; Accepted for publication: 25 November 2019; Published online:
30 January 2020
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The issue addressed in this guide
When considering nanoparticle (NP) distribution, a question that is often raised is whether they enter the brain.
With the goal to useNPs to deliver drugs to the brain, many researchers are hopeful that their NPs do enter the brain.
Others are concerned about unintended NP brain entry and potential adverse effects. Many have oversimplified
the concept of brain entry. They have not considered the extensive vasculature that permeates the brain, and
the potential for an NP to be within the vasculature (blood), associated with components of the blood–brain
barrier (BBB) or blood–cerebrospinal fluid barrier (BCSFB), or in cerebrospinal fluid (CSF), rather than in brain
parenchyma that houses the brain cells and their extracellular (interstitial) space. This article aims: to inform
about the distinction between distribution into the brain (bulk brain) versus brain parenchyma, present methods
that can demonstrate brain parenchymal distribution, present a tiered classification of methods and results that
demonstrate bulk brain versus brain parenchymal distribution, critically review some reports that claimed brain
or brain parenchymal NP distribution and rate them according to the tiered classification, and suggest that NP
residence time in the brain often informs about brain parenchymal entry.
BBB anatomy & function
To justify the claim that an NP crossed the BBB and entered brain parenchyma requires an understanding of brain
anatomy, the vasculature within it and research methods that demonstrate brain parenchymal entry. The primary
route to enable NP brain parenchymal entry is across the BBB. The BBB separates the vascular compartment
from brain cells that are surrounded by extracellular/interstitial fluid that occupies approximately 20% of the
parenchymal space. The BBB includes brain microvascular endothelial cells (BMECs) that line microvessels within
the brain, forming the luminal (blood) side of the BBB (Figure 1). BMECs have efflux transporters that effectively
prevent brain parenchymal entry of many substances and metabolic enzymes to maintain brain homeostasis. On the
other hand, BMECs have influx transporters that deliver essential nutrients, elements and factors to brain cells from
the blood, supporting brain nutrition. Influx transporters have been utilized in a Trojan horse approach to hitchhike
NPs through the BBB to brain parenchyma. BMECs differ from endothelial cells that line the vasculature outside of
the brain by their near total absence of fenestrations (windows) through which NPs might diffuse and the presence
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Figure 1. Brain vasculature and components of the blood–brain barrier/neurovascular unit in relation to brain
parenchyma.
of tight junctions between adjacent BMEC surfaces. Intact tight junctions prevent passage of ionic substances as
small as lanthanum (hydrated ionic diameter ∼0.8 nm) through this paracellular barrier [1]. Microvessels, the blood
vessels between arteries and veins, are approximately 7.5 μm in diameter [2], barely large enough for a red blood
cell to squeeze through. Microvessels deliver blood to the brain from within the brain [3].
There are 100 billion capillaries, approximately 600 km long, with a surface area of 20 m2 within the human
brain. These microvessels provide a blood supply within approximately 10 μm of every brain cell [4], as illustrated
in Figure 1 by the foreground and two background microvessels. They occupy approximately 2% of cortical brain
volume and a greater space in some other brain regions [5,6]. Pericytes extend over approximately 30% of the BMEC
surface. Surrounding the BMECs and pericytes is a basement membrane, covering the abluminal (brain-side)
BMEC surface (Figure 1). Foot processes of astrocytes, one of the brain’s glial cells, cover more than 90% of the
abluminal basementmembrane surface (Figure 1). Neurons interact with this cell complex to form the neurovascular
unit (Figure 1). For an NP to enter brain parenchyma from blood, it must either distribute through a BMEC
(transcellular) or between BMECs (paracellular), as suggested in Figure 1. The latter is not expected when the BBB
is intact but can occur when the BBB is opened (leaky, e.g., there is increased space between adjoining BMEC
surfaces). This occurs in cancer (at the blood–tumor barrier), Alzheimer’s disease, traumatic brain injury, multiple
sclerosis, infections, encephalitis, stroke, liver failure and other less common conditions [7,8]. BBB opening can be
produced by osmotic insult, for example, 25% mannitol infusion into a carotid artery that delivers blood directly
to its ipsilateral hemisphere [9] or focused ultrasound in conjunction with systemically circulating microbubbles [10].
The potential pitfall of experimental result misinterpretation
Given the intimate spatial relationship between themicrovessels of the vascular compartment and brain parenchyma,
visual demonstration of brain parenchymal entry in vivo or in situ requires ≤10 μm resolution. Alternatively, one
could use methods that separate BBB components from brain parenchymal components. Failure to distinguish
brain parenchymal NP entry from bulk brain can result in the interpretation that an NP has crossed the BBB
when it may not have or did not to the extent implied. For example, IVIS demonstration of increased fluorescence
in the head region from an NP component does not differentiate whether the NP is in the skull; the blood in
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the vessels surrounding and within the brain; associated with the luminal side of BMECs; within or between the
BMECs; between the BMECs and basement membrane; within the basement membrane, pericytes or astrocyte
foot processes; or in brain parenchyma.
There have been many studies addressing brain entry of many different NPs that concluded they entered the
brain, without demonstration that they crossed the BBB and entered brain parenchyma. Considering the brain
as the cranial contents, the claim of NP brain entry can be accepted if it is shown that the NP is in bulk brain.
But this does not demonstrate brain parenchymal entry. For most studies, the methods employed were not able
to differentiate NPs in the blood versus associated with BBB components versus residing in brain parenchyma, as
differentiated in Figure 1.
NPs in or associated with the vascular compartment contribute to bulk brain but not brain
parenchymal content
Rats perfused to remove blood (from the vascular compartment) 4 h after intravenous injection of gold gly-
conanoparticles had only approximately 4% as much NP component in bulk brain as rats that had not been
perfused [11]. Similar perfusion reduced gold in three bulk brain regions to 7–18% of that seen in nonperfused
rats [12]. This demonstrates that a great percentage of NPs in bulk brain may not be in brain parenchyma. Re-
moval of blood from the entire body can be accomplished in the deeply anesthetized rodent by transcardial
perfusion; introducing a perfusate into the left ventricle and ligating the right auricle to allow blood and perfusate
drainage. Perfusate can be 0.9% sodium chloride or 0.1 mM phosphate @ pH 7.4. For electron microscopy, 4%
paraformaldehyde and 3.5% glutaraldehyde in cacodylate/phosphate-buffered saline/saline buffer should be used.
Gage et al. provide a protocol [13]. Some studies accounted for the contribution of blood NPs within the brain to
their bulk brain level [6,14–18]. NPs in bulk brain blood were estimated from the product of the peripheral blood NP
concentration × brain vascular volume. However, this does not account for NPs adsorbed to the BMEC luminal
wall or in BBB cellular and membrane components. After intravenous injection to rodents, NPs were observed
adhered to the luminal wall of blood vessels in the brain with little to no evidence of brain tissue entry. This was seen
for lipid (stearic acid and polysorbate 80) drug conjugate NPs [19], 100-nm wide and 300-nm long poly(ethylene
glycol) (PEG)-polyethylenimine-conjugated mesoporous silica NPs [20], and a 5-nm polyhedral citrate-coated ceria
NP that had a surface charge of -53 mV [21]. In Dan et al.’s study, blood was removed from the brain by ceria-free
perfusion. The preponderance of NPs in guinea pig brain that had been infused for 120 min with approximately
8-nm amphipathic hydrophilic/hydrophobic-coated gold/iron core NPs followed by 30 min perfusate washout was
in endothelial cells [22]. These observations are in agreement with a kinetic study that reported a negatively charged
NP associated with cell surfaces within seconds, by Langmuir adsorption through electrostatic interaction [23].
These results demonstrate the potential contribution of BBB-associated NPs to bulk brain content, even after
removal of blood from the brain.
The importance of distinguishing among NP distribution in the vascular compartment, the cells comprising the
BBB and brain parenchyma is nicely illustrated by the results of Fiandra et al. [24]. Employing fluorometric dye
fluorescein isothiocyanate (FITC)-labeled amphiphilic polymer-coated iron oxide NPs containing a fluorometric
dye (AF660)-labeled antiretroviral drug, they differentiated localization of the drug from the nanoconstruct.
Confocal laser scanning microscopy (CLSM) viewing of mouse brain sections stained to identify the BMECs
demonstrated colocalization of the NPs and BMECs, interpreted as NP residence in the vascular compartment.
Antiretroviral drug was seen within and outside of the vascular compartment, interpreted as having been released
from the NPs. Similarly, using a GFAP antibody to identify blood vessels by the astrocyte foot processes that cover
them, Dal Magro et al. saw considerable NPs surrounded by the GFAP antibody, but some particles that were not,
the latter interpreted as having entered brain parenchyma [25].
BCSFB anatomy & function
The CSF compartment is comprised of four ventricles within the brain (two lateral, a third and a fourth) and the
CSF-filled subarachnoid space that surrounds the entire CNS. CSF is produced by choroid plexuses in each of the
four ventricles and diffusion of extracellular fluid from the brain. Each lateral ventricle has a single outlet, to the
third ventricle, that drains into the fourth ventricle, that drains into the subarachnoid space, creating one-directional
flow out of the brain. CSF in the human and rat turns over approximately four- and ten-times daily, respectively.
It exits from this compartment through arachnoid granulations into dural sinuses then into blood (via the jugular
veins). The epithelial cells of the choroid plexuses have tight junctions, efflux transporters and metabolic properties
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Table 1. Studies that reported the brain level of the nanoparticle or component(s) at multiple times after convection
enhanced delivery. Mean residence time values were determined as described in nanoparticle kinetics in the brain.
Study summary MRT (h) Ref.
The percent of radioactivity in the brain following CED of 82 nm 3H-cholesteryl hexadecyl ether liposomes was determined 22 [83]
The rat brain hemisphere that received CED of 0.06, 0.8 or 1.6 mg of 96–101 nm irinotecan-loaded nanoliposomes was perfused and
homogenized, centrifuged,and irinotecan analyzed by the HPLC. Half-life of the three doses was 6.7, 10.7 and 19.7 days, respectively
108, 181and 400 [81]
Brains from rats that received CED of 105–122 nm topotecan-loaded liposomes was perfused, the infused hemisphere removed,
homogenized, centrifuged and topotecan analyzed by the HPLC. Half-life was 1.5 days
44 [84]
The rat brain hemisphere that received CED of a mixture of 95–110 nm doxorubicin-loaded pegylated liposomes or irinotecan-loaded
nanoliposomes was perfused, homogenized, centrifuged and irinotecan and doxorubicin analyzed by the HPLC. Half-life was 10.9 and
16.7 days, respectively
273 and305 [79]
Local retention of radioactivity after intratumor CED of 135 nm 186Re-loaded liposomes was determined in rat brain by gamma
camera. Half-clearance time was 54.6 h
50 [85]
Brain MRI was obtained after CED of human serum albumin-, PEG- and methotrexate/human serum albumin-coated 20 nm  -Fe2O3
NPs
190, 184and 198 [80]
IVIS imaging was conducted after CED of EGFR-coated quantum dot-containing immunoliposome hybrid NPs to mice with brain tumors 97 [86]
Positron emission tomography imaging was conducted after CED of 71 and 147 nm [18F]-fluorobenzylamine, NHS-PEG- biotinylated,
avidin-modified PLGA NPs to rats. Half-life was 111 min
0.39 [87]
Rat brain containing the region of CED of 175 nm carboplatin-labeled fluorescein-PLGA NPs was homogenized and platinum
determined by ICP–MS
18 [88]
The hemisphere that received CED of 60–100 nm radiosensitizer (VE822)-loaded PEG-conjugated,
poly(u-pentadecalactone-co-p-dioxanone) NPs, of varying PEG polymer ratios, was analyzed by LC–MS for VE822. Half-life was 12 h, 2
and 5 days
46, 61 and 68 [89]
Fluorescence images of mice brain sections were obtained after intrastriatal CED of Cy5.5 fluorophore-labeled peptide-based
nanofibers (5-nm width, 100, 400 and 1000 nm length)
20, 25 and 29 [29]
MRI imaging was conducted for 48 h after CED of 54-nm iron oxide chitosan-PEG NPs modified with a glioma-targeting ligand to
mice-bearing brain tumors. Signals near the point source of the infusion of NP without and with ligand were used to calculate the MRT
3.4 and4.8 [90]
CED: Convection-enhanced delivery; HPLC: High-performance liquid chromatography; ICP–MS: Inductively coupled plasma mass spectrometry; IVIS: In vivo imaging system; LC–
MS: Liquid chromatography-mass spectrometry; MRT: Mean residence time to the last sample; NHS: N-hydroxysuccinimide; NP: Nanoparticle; PEG: Polyethylene glycol; PLGA:
Poly(D,L-lactide-co-glycolide).
similar to the BBB, creating the BCSFB between blood and CSF. There is little barrier to distribution between
CSF and the brain, so substances injected into the CSF compartment, or able to cross the BCSFB, readily diffuse
into the brain proximal to the CSF compartment.
Material entry into the nervous system, including the brain, might also be achieved by its introduction into the
CSF compartment. In the human, this is most often accomplished by injection into CSF in the spinal region. Given
CSF flow, NP injection into CSF would not be expected to persist for a long time compared with introduction
into brain parenchymal space. As distribution from CSF into the CNS (brain and spinal cord) is by diffusion, and
against extracellular fluid flow toward CSF, significant distribution very far into the brain would not be expected.
Demonstration of successful NP distribution into brain parenchyma via this route would require similar techniques
as apply to NP introduction into blood.
Convection-enhanced delivery of solutions into brain extracellular space
A method to directly deliver solutions into the brain is convection-enhanced delivery (CED). In CED, the tip of a
catheter is stereotaxically inserted into the brain through a hole in the cranium. A solute (drug or NP)-containing
solution is infused through the catheter by a pump. Solute release from the catheter tip into brain extracellular space
displaces extracellular fluid. The solute distributes through brain extracellular space surrounding the catheter tip by
bulk flow to create a radial distribution up to a few centimeters. After termination of the infusion, the solute may
continue to redistribute by bulk flow and diffusion as it is being locally cleared. CED has advantages of bypassing
the BBB enabling brain parenchymal delivery of drugs that do not cross the BBB, delivery to a target site that can
be deep within the brain and creation of much higher regional than distal brain and systemic drug concentration.
It is most commonly used to treat glioblastoma multiforme, a brain cancer that has a poor prognosis [26–28]. Small
molecules are cleared within 72 h [29], whereas some NPs have been found to persist for much longer (Table 1 &
Supplementary Figure 1).
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Table 2. Visual methods that might be used to image brain nanoparticle distribution and their reported resolution.
Method Resolution Ref.
High-resolution brain MRI ≥120 μm [91]
Photoacoustic microscopy 20–100 μm [37]
IVIS spectrum 20 μm [92]
MSI Submicron for some methods [93]
Super resolution (light) microscopy (aka: single-molecule localization microscopy) 100 nm [38,94–96]
Hyperspectral imaging 10 nm [44,97,98]
CLSM 2 μm [99]
Electron microscopy 1 nm [100]
CLEM 50 nm for LM, 1 nm for EM [59,61]
CLEM: Correlative light and electron microscopy; CLSM: Confocal laser scanning microscopy; EM: Electron microscopy; IVIS: In vivo imaging system; LM: Light microscopy; MSI:
Mass spectrometry imaging.
The nasal cavity route of delivery directly to the CNS
There is only one site where the nervous system is directly exposed to the external environment of mammals,
where direct uptake of NPs into the nervous system might occur. This is the roof of the nasal cavity where the
olfactory neuron and the maxillary branch of the trigeminal neuron have terminals with receptors that mediate the
perception of sensory stimuli, including smell. This route of administration, introducing test material into the nose
(intranasal), is being investigated for NP entry into the brain, to bypass the BBB. Demonstration of NPs in these
sensory neurons ex vivo (e.g., by electron microscopy visualization or elemental analysis under conditions that rule
out dissolution or degradation that releases NP components), or of NPs within the nerve when it is in situ, provides
confidence of nerve entry. The olfactory and trigeminal neurons are surrounded by CSF, so suggestion of NP in
the region of the nerve, for example, from an NP fluorescent molecule, does not unequivocally show nerve entry.
Although neuropeptides have been shown to enter CSF directly from the nasal cavity, this route was shown to not
contribute to uptake of 110 nm 6-coumarin-loaded (for visualization) PEG-poly(lactic acid) NPs [30]. There have
been demonstrations of NP uptake by the olfactory or trigeminal nerve. NPs often accumulate in the olfactory bulb,
with little or no distribution across the synapse between the olfactory bulb and the next neuron of the olfactory
system that would enable distribution to distal brain regions (e.g., the pyriform cortex, amygdala, thalamic and
hypothalamic nuclei, and hippocampus) after intranasal administration. Olfactory bulb accumulation was shown
with colloidal gold [31,32], 13C carbon [33], nanoscale manganese oxide [34] and quantum dots [35]. Distribution
of quantum dots from the nasal cavity to the olfactory bulb was attributed to microtubule-mediated fast axonal
transport (200–400 mm/day), because axonal flow is too slow to account for the timecourse of its appearance in the
olfactory bulb [35]. Based on the olfactory nerve length from the nasal cavity to the olfactory bulb (∼5 and 8 mm in
mice and rats, respectively) fast axonal transport could traverse this with an NP in approximately 26–40 min. Much
more time would be required for neuronal NP transport from the nasal cavity to distant brain regions, such as the
striatum. Rapid appearance of NPs or NP components in distant sites can be attributed to absorption from the
nasal cavity into systemic circulation followed by distribution into the brain. Translocation of NPs from the nasal
cavity to the brain is low. Gamma counting of whole brain 24 h after intranasal 111In-labeled protein NP suggested
approximately 0.2% of the dose was in the brain, assuming stability of the 111In-NP complex [36]. No studies were
found demonstrating NP entry into brain parenchyma beyond the olfactory bulbs after intranasal administration.
Methods to demonstrate NP brain parenchymal entry
To definitively claim that an NP has entered brain parenchyma requires methods that differentiate NP distribution
in brain parenchyma from blood within the brain and BBB components. One approach is to use visual methods.
Visual methods to demonstrate NP brain parenchymal entry
Table 2 lists some visual methods and their optimal resolution. High-resolution brain MRI does not provide,
even under optimal conditions, sufficient resolution to differentiate NP localization between parenchymal versus
nonparenchymal sites. It would not be able to characterize NP morphology, size or chemical identity.
Photoacoustic imaging (tomography) is a hybrid imaging modality that integrates optical contrast with high-
ultrasonic spatial resolution in deep tissue. It can provide noninvasive images of the entire brain with less than msec
future science group 10.2217/nnm-2019-0169
Review Yokel
temporal resolution [37], based on the light absorption properties of the tissue and material (e.g., NPs) within it.
Although useful for NP-assisted imaging, for example, of brain tumors, it lacks sufficient resolution to differentiate
NP localization between parenchymal versus nonparenchymal sites.
The IVIS spectrum in vivo imaging system combines 2D and 3D optical tomography into a single platform to
visualize fluorescence and bioluminescence. It has been extensively used to demonstrate the intensity of fluorescent
NPs in organs in vivo and ex vivo. Intensity in the head region has been claimed by many as evidence of the NP
in the brain. It is noninvasive and can be used with living organisms. However, even if used to localize NPs in
ex vivo tissue, it does not have sufficient resolution to differentiate NP localization between parenchymal versus
nonparenchymal sites.
Mass spectrometry imaging (MSI) includes many techniques, such as laser desorption/ionization mass spec-
trometry, matrix-assisted laser desorption ionization, (time-of-flight) secondary ion mass (SIM) spectrometry and
desorption electrospray ionization. It has been used with surface-functionalized gold- or gadolinium-containing
NPs to localize organics such as lipids, metabolites and proteins in the brain. Although some forms of MSI have
submicron resolution (e.g., SIM), no reports were found using MSI to verify brain parenchymal NP localization.
Super-resolution microscopy utilizes fluorescent microscopes in a variety of approaches, categorized as those
that approach the diffraction limit (0.25 μm in the focal plane) and those that break the diffraction limit by
turning fluorescent markers on and off. In the latter rather than all fluorescent molecules emitting simultane-
ously (as occurs in conventional fluorescence microscopy), a small subpopulation is excited so that emission from
neighbors does not overlap, enabling isolation of individual emitters [38]. Approaches include stochastic optical
reconstruction microscopy, direct stochastic optical reconstruction microscopy, photoactivated localization mi-
croscopy, fluorescence photoactivated localization microscopy and ground-state depletion with individual molecule
return. Super-resolution microscopy has been used to image the NP protein corona [39,40] and localize NPs in
cells [41,42], but no reports were found of in vivo, in situ or ex vivo NP localization.
Hyperspectral imaging combines imaging and spectrophotometry by capturing spectral data of infrared and
visible light reflected by samples at each pixel in an enhanced dark-field microscopic image. For this to differentiate
vascular versus parenchymal NP localization, an enhanced dark-field microscopic image needs to be interpreted
first to identify the region of interest, then hyperspectral imaging employed to provide spectrophotometric data.
This was demonstrated in studies that showed cellular sites of functionalized gold NPs [43]; studies that included
cellular, C. elegans, and Japanese medaka NP distribution cited by Roth [44]; and porcine skin uptake of metal oxide
NPs [45]. This approach might enable differentiation of NP localization between brain parenchymal versus vascular
sites, but no such studies were found.
Fluorescence microscopy visualizes fluorescent tags or incorporated molecules (e.g., doxorubicin and paclitaxel).
With the exception of transmission electron microscopy (TEM), the only studies using a method in Table 2 that
appear to have differentiated NP parenchymal from vascular space distribution used fluorescence microscopy and
CLSM. Using fluorescence microscopy, Mulik et al. saw fluorescent-labeled NPs within brain cells [46]. A˚slund et
al. used CLSM to image fluorescent dye-containing NPs, and tomato lectin-labeled blood vessels, and saw NP
fluorescent dye outside of the brain microvasculature [47]. Some details of these studies and those reported by others
who used CLSM are below and/or in Table 4 [22,24,25,47–55].
Electron microscopy, typically TEM, is not only the best technique to characterize prepared NPs, it is also
amenable to physicochemically identify and characterize NPs in samples obtained from biological environments [56–
58]. It provides the greatest resolution among the options in Table 2, and when equipped with capabilities such as
high-angle annular dark-field detection, energy dispersive x-ray spectroscopy or electron energy loss spectroscopy,
it enables chemical characterization.
The benefits of light microscopy (including identification of biological structures and location of regions of
interest and fluorescent labels) have been combined with the benefits of electron microscopy (to provide NP
localization and physicochemical information) in correlative light and electron microscopy (CLEM) [59]. The two
approaches were independently used to locate NPs in a murine brain tumor model [60]. CLEM has been developed
in a single instrument and used to localize NPs in cultured non-neuronal cells [61]. No studies were found utilizing
CLEM to investigate NP brain parenchymal entry.
Several of the above methods are based on detection of a label added to the NP, often a fluorescent molecule or
metal/metal oxide. Correct interpretation ofNP localization, when based on an added label, requiresNPpreparation
that does not contain free label (which can be removed by dialysis) and understanding the label stability in vivo.
Fluorescent molecules are susceptible to loss of their signal due to quenching (due to interaction with local molecular
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environmental components) and photobleaching (excitation light-induced destruction of the excited fluorophore).
Persistent association (stability) of the label and the NP in vivo is required to attribute label signal to NP localization.
Label dissociated from the NP will yield a different distribution than the label-NP complex. Covalent binding of
label to an NP decreased label release, compared with encapsulation of the label [62]. Incorporation of the label in
the NP core did not produce changes in the NP surface properties [63]. Label dissociation from a biodegradable
polymer NP would be expected over time. Label dissociation can be assessed in vitro by incubation of the labeled
NP with brain homogenate [30] or separation of the NP and brain components from the released label, for example,
by NP centrifugation, and detection of label in the supernatant. Other considerations include the potential for the
label to alter the physicochemical properties of the NP and its resultant distribution and biological tolerance to the
label. More in-depth discussions can be found in [64,65].
Procedural methods to demonstrate NP brain parenchymal entry
Methods are available to assess whether NPs introduced into the vasculature perfusing the brain are associated with
BBB components and/or crossed the BBB to enter brain parenchyma. The in situ brain perfusion technique can
be used to determine NP entry rate and extent of distribution into bulk brain, multiple bulk brain regions and/or
the choroid plexus, ipsilateral to the carotid artery perfused after short-term (few minutes or less) intracarotid
infusion [66]. An intracarotid perfusion rate sufficiently high to prevent blood from entering the perfused carotid
artery is used, therefore preventing blood from entering the brain hemisphere perfused by that artery. This enables
control of the chemical environment of the material tested (therefore its chemical form [speciation]), based on
the perfusion fluid composition and avoidance of blood exposure. Preventing blood exposure avoids potential NP
biotransformation (e.g., corona coating by plasma proteins, dissolution or particle breakdown) that might change
its surface properties and brain uptake. Although the in situ brain perfusion technique removes blood from the
brain vasculature, it does not distinguish NP distribution associated with the BBB versus brain parenchyma, nor
choroid plexuses from brain unless they are separated.
The capillary depletion method is intended to separate BBB components from brain parenchyma, to produce
capillary-depleted brain parenchyma [67]. This is often conducted with brain tissue obtained using the in situ brain
perfusion technique but can be used with brain tissue obtained by other methods that remove blood from the
brain. The methods are described in detail in [68]. The capillary depletion method uses centrifugation of brain
homogenate in dextran that separates the BMECs into the pellet (along with brain nuclei and erythrocytes if
blood was not perfused from the brain) from the supernatant that contains brain cells and brain extracellular
fluid. Presence of the test material in the supernatant is taken as evidence that it has transcytosed the BBB into
brain parenchyma. This method was employed to ascertain the fraction of 190-nm poly(n-butyl cyanoacrylate)
(PBCA)-coated doxorubicin-loaded NPs that entered brain parenchyma [69]. Doxorubicin was seen in the brain
fraction after intravenous administration in NPs but not when doxorubicin solution was administered with 1%
polysorbate 80 (intended to open the BBB). Coating the NPs with 1% polysorbate 80 increased the doxorubicin
supernatant to pellet ratio, suggesting the surfactant-coated PBCA NPs entered brain parenchyma. Employing
the capillary depletion method after whole body perfusion to remove blood, it was shown that the percentage of
the injected dose of [111In-DTPA-multiwalled carbon nanotubes (median diameter: 18.9 and length: 500 nm)
decreased in brain capillaries but not brain parenchyma over 24 h [70]. The capillary depletion method was used
to obtain curcumin for LC–MS/MS analysis from mouse brains after oral dosing of a curcumin-containing NP.
The report does not state if the brain was perfused prior to harvest. If not the supernatant fraction would be
expected to include blood plasma contents that could have contained some/all of the curcumin [71]. The capillary
depletionmethodwas used to demonstrate that cationic bovine serum albumin-coated biodegradable polymersomes
(∼100 nm, composed of PEG- and maleimide-PEG-poly(ε-caprolactone), loaded with coumarin-6) entered brain
parenchyma. The supernatant fraction increased from a half to 1 h and was fairly stable for 4 h, and increased over
the 4 h in relation to the pellet (vascular fraction) [72]. Capillary depletion was used in transcardially perfused mice
to assess the influence of transferrin-receptor antibody density on gold NPs and platinum-containing liposomes
to enter brain parenchyma [73]. 2.5 h after intravenous injection, gold and platinum in the parenchymal fraction
were approximately 27 and 22% of the combined parenchymal and capillary fractions, respectively. In contrast to
demonstrating brain parenchymal entry, the capillary depletion method suggested nearly all of 5-nm ceria in the
brain was associated with the capillary endothelial cells, consistent with EM observations of nanoceria adhered to
the luminal side of blood vessel walls in the brain, noted above [21].
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Table 3. A classification of results demonstrating brain versus. brain parenchymal entry.
Level Description of results Interpretation
1 NP component (e.g., fluorescent dye, element) in bulk brain or ex vivo brain not perfused of
blood. Determined by methods such as IVIS, radioactivity, NAA, ICP–MS, AAS or HPLC
A NP component was in bulk brain
2 NP component (e.g., fluorescent dye, element) in bulk brain or ex vivo brain perfused to
remove blood. Determined by methods such as IVIS, radioactivity, NAA, ICP–MS, AAS or HPLC
A NP component was in bulk brain, but not in the
blood within the brain
3 Intact NP in bulk brain not perfused of blood. Determined by methods such as bulk
brainhomogenization, NP isolation and verification (e.g., visual, perhaps also requiring
chemical)
The NP was in bulk brain
4 Intact NP in bulk brain perfused to remove blood. Determined by methods such as bulk brain
homogenization after perfusion to remove blood, NP isolation and verification (e.g., visual,
perhaps also requiring chemical)
The NP was in bulk brain, but not in the blood
within the brain
5 NP component isolated from brain parenchyma. For example, using the capillary depletion
method of brain perfused to remove blood to obtain brain parenchyma and a method to
identify the NP component, for example, radioactivity, ICP–MS, AAS or HPLC. For example,
microdialysis to recover an NP component from brain extracellular fluid, in the presence of an
intact BBB
A NP component was in brain parenchyma
5 NP component (e.g., fluorescent dye, element) visualized in brain areas or cells not associated
with brain vasculature. Determined by methods such as MSI, single-molecule localization
microscopy, hyperspectral imaging or CLSM
A NP component was in brain parenchyma
6 Intact NP isolated from brain parenchyma. For example, using the capillary depletion method
of brain perfused to remove blood to obtain brain parenchyma and a method to verify intact
NPs (e.g., visual, perhaps also requiring chemical)
The NP was in brain parenchyma
6 Intact NP visualized in brain areas or cells not associated with brain vasculature.
Determined by methods such as TEM, with chemical verification, such as EDS or EELS
The NP was in brain parenchyma
The level of demonstration of nanoparticle brain or brain parenchymal entry is in the first column.
AAS: Atomic absorption spectroscopy; BBB: Blood–brain barrier; CLSM: Confocal laser scanning microscopy; EDS: Energy dispersive x-ray spectroscopy; EELS: Electron energy loss
spectroscopy; HPLC: High-performance liquid chromatography; ICP–MS: Inductively coupled plasma–mass spectrometry; IVIS: In vivo imaging system; MSI: Mass spectrometry
imaging; NAA: Neutron activation analysis; NP: Nanoparticle; TEM: Transmission electron microscopy.
NP components have been sampled from the brain using microdialysis probes [74–77]. In the presence of an intact
BBB, it is assumed that this technique samples brain extracellular space. Microdialysis probes with 30 and 100 kDa
molecular weight cutoff membranes would be expected to allow penetration of up to 5–8 and 8–14 nm (depending
on membrane composition) diameter spherical particles and molecules released from NPs. The appearance of an
NP component in the dialysate from a probe would not conclusively demonstrate NP distribution into brain
parenchyma. None of the above studies demonstrated that intact NPs were recovered in the dialysate.
Level of demonstration of NP brain or brain parenchymal entry & critical review of study
claims
Convincing demonstration of brain parenchymal entry is limited to in vivo studies. In vitro BBB models do not
recapitulate BBB complexity. They lack all of its cell composition, cell interactions, cell spatial relationships and
magnitude of resistance to distribution across them. Therefore, this report is limited to in vivo, in situ and ex vivo
brain studies. Many reports published within the past 5 years were identified by a SciFinder search of the terms NP
and brain, a SciFinder search of the terms NP and BBB for reports published in 2019, and a PubMed search of NPs,
drug delivery systems and brain parenchyma. The reports were reviewed, summarized and critiqued for evidence
supporting claims in the report and classified for the level of demonstration of NP brain or brain parenchymal entry,
as defined in Table 3. Some reports published more than 5 years ago that are informative for their demonstration of
NP brain parenchymal entry and/or reported brain NP concentration at multiple times are included. The results
are in Table 4.
NP kinetics in the brain
Endocytosis is the prevalent mechanism that mediates NP transport across the intact BBB. It would not be
anticipated that after NPs cross the BBB and enter brain parenchyma they would be rapidly cleared from that
compartment [78]. After NP infusion directly into the brain by CED, HPLC determination of two components
showed clearance half-lives of 250–400 h (Table 1) [79]. MRI-determined NP distribution volume after CED
decreased 50% in approximately 250 h (Table 1) [80]. Some details of these and other studies that reported brain
NP or component levels at multiple times after CED are in Table 1. Brain clearance half-life was shown to be dose
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Table 4. Brain nanoparticle distribution study claims, summary, critique, support for the claims and level of brain
or brain parenchymal entry.
Claim Study summary Critique, support for claim and
level of demonstrated NP brain
entry
MRT (h) Ref.
Uptake of NPs in thebrain Whole organs were solubilized for radioactivity
determination after iv. injection of 131-nm
surfactant-coated poly(14C-methyl methacrylate) particles
Claim assumes intact NP
distribution to the brain, which is
not shown. Bulk brain 14C
presence shown; 1
42 (47) [101]
Doxorubicin was in brain tissue Whole organs were homogenized, proteins
precipitatedand doxorubicin determined by HPLC after iv.
injection of 90-nm doxorubicin-loaded solid lipid particles
HPLC results of NP component
show bulk brain uptake; 1
1.8 (1.8) [102]
‘Polysorbate 80-coated
polybutylcyanoacrylate NPs could
be used to overcome blood–brain
barrier’
Visible blood vessels were removed from the cerebrum and
cerebellum, whole organs were homogenized, proteins
precipitated and methotrexate determined by HPLC after
iv. injection of 70–345 nm methotrexate-loaded PBCA NPs
HPLC analysis of NP component
in bulk brain does not
demonstrate distribution across
the BBB; 1
1.8 and1.9 [103]
‘ICP–MS results indicated that 17
and 37 nm [gold NPs] were
capable of passing through the
blood–brain barrier and entering
the mouse brain.’
aWhole brain was homogenized, separated by HPLC,and
gold quantified by ICP–MS after ip. injection of 17- and
37-nm gold particles.
bTEM and EDS showed electron-dense particles in the
cytoplasm of hippocampal pyramidal cells and gold
aICP–MS results of NP component
in bulk brain do not demonstrate
distribution through the BBB; 1.
bTEM/EDS results demonstrate
distribution across the BBB; 6
Increased from
336to 504
hafterinjection
[104]
Brain delivery Whole brain from transcardially perfused rats was
homogenized for gold quantitation by NAA after ip.
injection of peptide-conjugated,citrate-coated 12-nm gold
particles.Whole brain from transcardially perfused rats was
prepared for fluorescence microscopy after ip. injection of
carboxyfluorescein-labeled,peptide-conjugated,
citrate-coated 12-nm gold particles
NAA results of NP component in
brain homogenate and
concurrent fluorescence show
bulk brain uptake; 2
No consistent
increase or
decrease over
24 h
[105]
‘Focused ultrasound and
magnetic targeting
synergistically delivers
therapeutic MNPs across the
blood–brain barrier to enter the
brain’
aWhole brain was prepared for ICP–OES iron and HPLC
epirubicin determination after iv. injection of 12-nm
magnetic NPs into rats whose BBB had been opened by iv.
injection of microbubbles and focused ultrasound.
bTEM of similarly treated rats with brain tumors showed
electron densities inside tumor cells and macrophages
aICP–OES and HPLC demonstrate
bulk brain but not parenchymal
entry; 1.
bTEM demonstrates delivery
across the BBB in the presence of
BBB opening, assuming the
electron densities are iron; 6
11 [106]
‘NP deposits were widely
distributed throughout brain,
with apparent cellular uptake’
aMicroscopic assessment of sections from rat brain after
intranasal dosing of 299-nm fluorescent- and
ovalbumin-loaded cationic liposomes revealed the label in
the striatum and substantia nigra.
bProtein immunohistochemistry of perfused rat brain
demonstrated protein and tyrosine hydroxylase
co-localization in striatum and substantia nigra.
cGamma counting of whole brain after intranasal dosing
of 50 μg 111In-labeled NP in 1 or 2 μg/μl suggested
approximately 0.2% of the dose was in the brain,
assuming stability of the 111In-NP
aImage shows increased
fluorescence within cells; 5.
bColocalization shows
fluorescence from NP within
cells; 5
c4.3 and2.1 [36]
‘[Curcumin-loaded PLGA NPs]
could cross the blood–brain
barrier (BBB) to enter brain
tissue’
Brains from perfused rats were dissected into parts,
homogenized,proteins precipitated and curcumin
determined by HPLC after iv. injection of 163-nm
curcumin-loaded PLGA NPs Reported MRT was 27 min
HPLC analysis of NP component
in bulk brain does not
demonstrate distribution across
the BBB; 2
0.36(0.33) [107]
‘In vivo brain distribution . . .
monitored by a real-time
fluorescence imaging system’
The whole rat and ex vivo brain were bioluminescence
imaged using IVIS and fluorescence microscopic images
obtained of brain sections after iv. injection of
190–210 nm fluorescent dye-labeled solid lipid particles
Imaging demonstrates bulk brain
distribution; 1
0.45 [108]
Brain delivery Fluorescence intensity was determined in ex vivo organs
from perfused rats after intranasal dosing of
odorranalectin-conjugated fluorescent-labeled 90-nm
PEG-PLGA NPs
Fluorescence intensity of brain
demonstrates bulk brain delivery;
2
5.2 [109]
Mean residence time from studies that reported brain and blood (in parentheses) levels at multiple times after dosing. Study multiple end points are designated by a, b, c before
the study summary and critique. The level of demonstrated nanoparticle brain entry is from the classification described in Table 3. The numbers after the sentences in column
3 refer to the level of demonstrated NP brain entry.
AAS: Atomic absorption spectroscopy; BBB: Blood–brain barrier; BBTB: Blood-brain tumor barrier; BMEC: Brain microvascular endothelial cell; BSA: Bovine serum albumin; CLSM:
Confocal laser scanning microscopy; EDS: Energy dispersive x-ray spectroscopy; EELS: Electron energy loss spectroscopy; FITC: Fluorescein isothiocyanate; ICP–MS: Inductively
coupled plasma–mass spectrometry; ICP–OES: Inductively coupled plasma–optical emission spectroscopy; INAA: Instrumental neutron activation analysis; ip.: Intraperitoneal; iv.:
Intravenous; IVIS: In vivo imaging system; MRT: Mean residence time; MSI: Mass spectrometry imaging; NAA: Neutron activation analysis; NP: Nanoparticle; PBCA: Poly(n-butyl
cyanoacrylate); RVG: Rabies virus glycoprotein; TEM: Transmission electron microscopy.
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Table 4. Brain nanoparticle distribution study claims, summary, critique, support for the claims and level of brain
or brain parenchymal entry. (cont.).
Claim Study summary Critique, support for claim and
level of demonstrated NP brain
entry
MRT (h) Ref.
‘We observed . . . a fourfold
increase of silver content . . .
which indicates that AgNPs are
able to cross the blood–brain
barrier (BBB)’
‘AgNPs also gained access to the
brain . . . visible as single NPs as
well as clusters’
aBrain from perfused rats was digested and silver
determined by ICP–MS after iv. 20- and 200-nm silver NP
injection.
bTEM showed electron-dense particles and clusters of
particles in brain cells. Their elemental composition was
not reported
aICP–MS results of NP component
in bulk brain does not
demonstrate distribution across
the BBB; 1.
bNPs crossed the BBB if the
electron dense particles
contained silver that was not the
result of dissolution then
precipitation; 6
Increased from
24 to 672 h after
injection
[110]
‘NPs were localized in the brain
parenchyma’
aGold in brains from perfused rats was determined by
INAA after ip. injection of transferrin receptor targeting
and -amyloid destroying peptides conjugated to 37-nm
gold NPs.
bTEM of hippocampus and cortex of perfused rats after ip.
injection of these gold NPs demonstrated intracellular
electron dense spots
aINAA results of NP component
in bulk brain do not demonstrate
distribution across the BBB; 1.
bNP seen in brain parenchyma; 6,
assuming the spots were gold NPs
8.8 [111]
‘Suggest that the OX-26-coated
NPs were taken up by the brain’
Microdialysis samples were obtained from the ventral
hippocampus for fluorescence detection of FITC-dextran
after iv. administration of 140–160 nm CD71/OX26-coated
FITC-dextran loaded methoxy-PEG-poly(lactic acid) NPs
NPs were too large to diffuse
through the microdialysis
membrane suggesting
FITC-dextran release; 5, assuming
intact BBB
21 [74]
‘Brain endothelial uptake and
possibly parenchymal
accumulation’
CLSM of fixed brain sections after carotid artery (in situ
brain) perfusion and washout of perfusate or iv. injection
of fluorescent dye-labeled,
polyethylenimine/oligonucleotide-containing liposomes
showed fluorescence associated with BMECs and in the
perivascular space between the BMEC membrane and
parenchymal basement membrane
NP or a component seen beyond
BMECs but not in brain
parenchyma; 2
[51]
‘NPs possess an appreciable BBB
penetrability’
Microdialysis samples were obtained from the right
ventrolateral periaqueductal gray for fluorescence
detection of FITC-neurotoxin after intranasal dosing of
145-nm chitosan-modified PLA FITC-neurotoxin-containing
NPs
NPs were too large to diffuse
through microdialysis membrane
suggesting FITC- neurotoxin
release; 5, assuming intact BBB
3.3 [75]
‘Accumulation was achieved in
the brain’
Whole brains from mice were homogenized, proteins
precipitated, and camptothecin determined by HPLC after
iv. injection of 160 nm camptothecin-containing solid lipid
NPs.
HPLC analysis demonstrates bulk
brain accumulation; 1
7.7(7.0) [112]
‘[Palmitoyl dalargin] was
detectable . . . in the brain’ ‘pDal
is clearly located in the brain
parenchyma’
aWhole brains were homogenized, proteins precipitated
and palmitoyl dalargin measured by LC-MS in rats after iv.
injection of palmitoyl dalargin fibers. The authors claim
brain parenchymal entry because brain concentration was
greater than can be accounted for by blood, and slower
clearance from brain than blood.
bCoherent anti-Stokes Raman scattering microscopy
revealed pDal fibers within brain parenchyma
aLC–MS of NP component in bulk
brain does not rule out BMEC
adsorption or incorporation; 1.
bMicroscopy demonstrated brain
parenchymal fiber entry; 6
0.86(0.17) [113]
‘Ag detected in the brain and
passing through the blood–brain
barrier (i.e., not localized in the
vessels and capillaries) constitutes
no less than 93% of the total
content of Ag in the organ’
Silver and gold were determined by NAA in brain of
exsanguinated rats after 14 or 28 daily intragastric
administrations of 35-nm silver and gold NPs. The authors
calculated brain metal from its concentration in blood and
brain blood mass
This does not account for metal
in BMECs. Silver could be ion
released from NP dissolution.
BBB Ag passage not shown; 2
[14]
‘In vivo studies indicated BBB
penetration of intravenously
injected TIMP-1 NPs + Ps80’
Confocal microscopy (40× objective)
immunohistochemistry of brain slices from perfused mice
after iv. injection of polysorbate 80-coated coumarin
6-containing protein-loaded PLGA NPs showed a few
positive spots
Spot location (intra- vs
extravascular) cannot be
determined. BBB penetration not
demonstrated; 2
[114]
Mean residence time from studies that reported brain and blood (in parentheses) levels at multiple times after dosing. Study multiple end points are designated by a, b, c before
the study summary and critique. The level of demonstrated nanoparticle brain entry is from the classification described in Table 3. The numbers after the sentences in column
3 refer to the level of demonstrated NP brain entry.
AAS: Atomic absorption spectroscopy; BBB: Blood–brain barrier; BBTB: Blood-brain tumor barrier; BMEC: Brain microvascular endothelial cell; BSA: Bovine serum albumin; CLSM:
Confocal laser scanning microscopy; EDS: Energy dispersive x-ray spectroscopy; EELS: Electron energy loss spectroscopy; FITC: Fluorescein isothiocyanate; ICP–MS: Inductively
coupled plasma–mass spectrometry; ICP–OES: Inductively coupled plasma–optical emission spectroscopy; INAA: Instrumental neutron activation analysis; ip.: Intraperitoneal; iv.:
Intravenous; IVIS: In vivo imaging system; MRT: Mean residence time; MSI: Mass spectrometry imaging; NAA: Neutron activation analysis; NP: Nanoparticle; PBCA: Poly(n-butyl
cyanoacrylate); RVG: Rabies virus glycoprotein; TEM: Transmission electron microscopy.
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Table 4. Brain nanoparticle distribution study claims, summary, critique, support for the claims and level of brain
or brain parenchymal entry. (cont.).
Claim Study summary Critique, support for claim and
level of demonstrated NP brain
entry
MRT (h) Ref.
‘BBB-penetrating cancer
cell-targeting delivery system’
aWhole animal and ex vivo brain IVIS imaging were
conducted after iv. 85-nm fluorescent-labeled,
doxorubicin-loaded desoctanoyl ghrelin and folate
conjugated-polymersome administration to brain
tumor-bearing mice.
bBrains from brain tumor-bearing perfused rats were
homogenized, proteins precipitated and doxorubicin
determined by HPLC after iv. injection of 85-nm
fluorescent-labeled, doxorubicin-loaded desoctanoyl
ghrelin and folate-conjugated polymersomes
aWhole brain results using this
method do not have sufficient
resolution to demonstrate BBB
penetration; 1.
bHPLC analysis of NP component
in bulk brain does not
demonstrate BBB penetration; 2
[115]
‘Targeted 68Ga-GNPs improves
BBB crossing’
Whole brains from perfused rats were gamma counted
after iv. injection of glucose conjugate-coated-68Ga-gold
NPs. Brain gold content was determined by ICP–MS
Whole brain radioactivity and
ICP–MS results of NP component
in bulk brain do not verify BBB
crossing; 2
[11]
Brain delivery Whole organs were homogenized and Bacoside-A
determined by HPLC after ip. administration of 173-nm
polysorbate 80-coated, Bacoside-A-loaded PLGA NPs to
rats
HPLC analysis of NP component
demonstrates bulk brain
delivery; 1
[116]
‘Brain bioavailability of
breviscapine from the
Bre-GBSLN-PS and
Bre-GBSLN-PS-DSPE was
significantly enhanced’
Fifteen kDa cutoff (∼5 nm) microdialysis probes were used
to obtain dialysate from rat brain after iv. injection of
23-nm PEG, stearate, 1,2-distearoyl-snglycero-3-
phosphoethanolamine-N-PEG2000-coated
breviscapine-loaded solid lipid NPs. The primary active
component of breviscapine was measured by HPLC
NP released component does not
identify NP brain location; 5,
assuming intact BBB
No decrease
from 3 to 12 h
after
injection(0.61)
[76]
‘We . . . demonstrated the ability
of these [gelatin NPs] to pass into
the brain parenchyma following
intranasal administration’
SEM of rat brain 6 h after intranasal administration of
184-nm gelatin NPs showed clusters of approximately
40-nm spherical particles in the olfactory tract, cortex,
striatum, amygdala and hypothalamus as evidence of NP
brain parenchymal entry
Assuming the observed particles
were gelatin NPs, perhaps
smaller due to tissue processing,
the results suggest brain
parenchymal entry; 5
[117]
‘Migration to brain parenchyma’
‘albumin modulates the
transport across the blood–brain
barrier’
aWhole brain radioactivity was determined by
gamma-scintigraphy of isolated mouse brain after iv.
albumin-coated 15-nm 198Au NP injection.
bBrain confocal microscopic images were obtained after iv.
fluorescent-labeled albumin-coated 198Au NP injection
aWhole brain radioactivity does
not verify transport across the
BBB into brain parenchyma; 1.
bResolution is not sufficient to
differentiate vascular from brain
parenchymal distribution; 1
21(5.1) [17]
‘Particles that actually crossed
the BBB’
Gold was determined by flame AAS analysis in brain from
mice that received iv. injection of 20-nm insulin
PEG-coated gold particles. Brain gold was calculated from
its blood concentration and brain–blood volume
This does not account for gold
associated with BMECs that the
authors hypothesize accounted
for gold in the brain at late time
points; 1
11(blood did not
decrease over
48 h)
[118]
Coumarin distribution to the
glioma region
aBrains from glioma-bearing mice were homogenized,
coumarin-6 extracted and quantified by HPLC after iv.
injection of 94-nm coumarin-6, L-13R2 ligand-coated
PEG-PLGA NPs.
bFluorescence spots were seen in the brain
aHPLC analysis of NP component
demonstrates bulk brain
distribution; 1.
bMicroscopy resolution only
sufficient to demonstrate brain
distribution; 1
[119]
Brain uptake Radioactivity determined by gamma-scintigraphy of
isolated whole mouse brain after iv. injection of 9- and
40-nm diameter, 396- and 268-nm length
[111In]-DTPA-multiwalled carbon nanotubes
Radioactivity demonstrates
distribution of NP or component
in bulk brain; 1
[120]
‘Gold would presumably not be
cleared from brain in such a short
timeframe if it has entered the
brain parenchyma’
Brains from mice were digested and gold determined by
ICP–OES after iv. injection of 80-nm biodegradable
polymeric micelles with 5 nm gold NP cores
ICP–OES results of NP component
in bulk brain do not show brain
parenchymal entry; 1
43(7.7) [78]
Mean residence time from studies that reported brain and blood (in parentheses) levels at multiple times after dosing. Study multiple end points are designated by a, b, c before
the study summary and critique. The level of demonstrated nanoparticle brain entry is from the classification described in Table 3. The numbers after the sentences in column
3 refer to the level of demonstrated NP brain entry.
AAS: Atomic absorption spectroscopy; BBB: Blood–brain barrier; BBTB: Blood-brain tumor barrier; BMEC: Brain microvascular endothelial cell; BSA: Bovine serum albumin; CLSM:
Confocal laser scanning microscopy; EDS: Energy dispersive x-ray spectroscopy; EELS: Electron energy loss spectroscopy; FITC: Fluorescein isothiocyanate; ICP–MS: Inductively
coupled plasma–mass spectrometry; ICP–OES: Inductively coupled plasma–optical emission spectroscopy; INAA: Instrumental neutron activation analysis; ip.: Intraperitoneal; iv.:
Intravenous; IVIS: In vivo imaging system; MRT: Mean residence time; MSI: Mass spectrometry imaging; NAA: Neutron activation analysis; NP: Nanoparticle; PBCA: Poly(n-butyl
cyanoacrylate); RVG: Rabies virus glycoprotein; TEM: Transmission electron microscopy.
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Table 4. Brain nanoparticle distribution study claims, summary, critique, support for the claims and level of brain
or brain parenchymal entry. (cont.).
Claim Study summary Critique, support for claim and
level of demonstrated NP brain
entry
MRT (h) Ref.
‘Demonstrated that the NPs
could cross the BBB’
CLSM images were obtained of brain tissue cryosections,
stained with tomato lectin to label blood vessels, from rats
that received iv. microbubbles and focused ultrasound to
open the BBB before iv. injection of 177-nm fluorescent
dye-containing PBCA NPs
Fluorescent spots attributed to
the fluorescent dye near the
blood vessels suggest NPs crossed
the BBB in the presence of
opened BBB; 6
[47]
‘The peptide was able to diffuse
outside the BBB, while NPs were
restricted to the vessel
endothelium’
CLSM images of brain sections with antibody-stained
BMECs from mice iv. dosed with 35-nm fluorometric
dye-labeled amphiphilic polymer-coated iron oxide NPs
containing a fluorometric dye-labeled antiretroviral drug
enabled distinction among microvessels, NPs and drug.
The NPs and BMECs were co-localized. The antiretroviral
drug was seen within and outside of the vascular
compartment, in brain parenchyma
Peptide fluorescence was seen in
brain parenchyma; 5
[24]
‘Distributed into the brain tissue’ The capillary depletion method was used to obtain a
non-BMEC fraction of mouse brains for LC–MS/MS
curcumin analysis after oral dosing of 139, 312 and 412 nm
uncoated, chitosan- and N-trimethyl chitosan-coated,
curcumin-loaded solid lipid NPs
Most of the whole brain
curcumin was in the supernatant
fraction, not associated with
BMECs, but could have come
from blood; 1
[71]
‘BBB penetration by AuNPs’ aGold content was determined by ICP–MS in brain from
perfused rats that received ip. injection of 1.3-nm gold
NPs.
bGold was determined by laser ablation ICP–MS in brain
sections
aICP–MS results of NP component
in bulk brain do not verify BBB
penetration; 2.
bLA-ICP–MS resolution not
sufficient to verify BBB
penetration. 2
8.7(4.4) [12]
The increase of brain iron from
days 1 to 7 ‘suggested the
smaller IOMNs crossed the
blood–brain barrier’
Iron was quantitated by AAS in solubilized whole organs
from mice that received iv. 10-nm carboxyl-coated iron
oxide magnetic NPs
AAS results of NP component in
bulk brain do not verify BBB
crossing; 1
Increased from
24 to 168 h after
injection
[121]
‘Exosome delivered anticancer
drugs crossed the BBB and
entered into the brain’
Fluorescent dye-, paclitaxel- or doxorubicin-labeled
mouse-derived 50 nm BMEC exosomes were iv. injected
into zebrafish transgenic for vasculature GFP expression
CLSM suggests NP fluorescence
and shows drug fluorescence
outside of the vasculature; 5
[48]
‘Nose-to-brain transport’ Cyclosporine A was extracted from homogenized olfactory
bulb and hind brain samples and quantitated by
LC–MS/MS after intranasal dosing of 272-nm
nanoemulsion to the rat
LC–MS/MS NP component shows
bulk brain distribution; 1
2.4 and 2.6 [122]
‘NPs were capable of penetrating
cell membranes and entering
cellular compartments’
Brains from mice with green fluorescent
protein-expressing tumors were imaged using CLSM after
iv. injection of 165-nm fluorescent dye-labeled
poly(amineco-ester) terpolymer NPs. PECAM (in BMECs)
was labeled. NPs were visualized around tumor blood
vessels and within a cell
Brain parenchymal NP entry
shown in tumor cells; 6
[49]
Brain accumulation at the site of
injury
Whole-body IVIS images were obtained after iv.
administration of approximately 170-nm
fluorescent-labeled siRNA-containing biodegradable
mesoporous silica, encapsulated in graphene oxide
nanosheets. Fluorescence was seen in the hemisphere of
mice with damaged brain
Greater fluorescence in brain at
the injury site supports brain
accumulation; 1
[123]
‘NP was obviously accumulated in
brain’
Imaging demonstrated mouse whole brain fluorescence
after iv. injection of approximately 180-nm cyclic
peptide-modified fluorescence dye-loaded PEG-poly(lactic
acid) NPs
Fluorescence demonstrates brain
accumulation; 1
[124]
Mean residence time from studies that reported brain and blood (in parentheses) levels at multiple times after dosing. Study multiple end points are designated by a, b, c before
the study summary and critique. The level of demonstrated nanoparticle brain entry is from the classification described in Table 3. The numbers after the sentences in column
3 refer to the level of demonstrated NP brain entry.
AAS: Atomic absorption spectroscopy; BBB: Blood–brain barrier; BBTB: Blood-brain tumor barrier; BMEC: Brain microvascular endothelial cell; BSA: Bovine serum albumin; CLSM:
Confocal laser scanning microscopy; EDS: Energy dispersive x-ray spectroscopy; EELS: Electron energy loss spectroscopy; FITC: Fluorescein isothiocyanate; ICP–MS: Inductively
coupled plasma–mass spectrometry; ICP–OES: Inductively coupled plasma–optical emission spectroscopy; INAA: Instrumental neutron activation analysis; ip.: Intraperitoneal; iv.:
Intravenous; IVIS: In vivo imaging system; MRT: Mean residence time; MSI: Mass spectrometry imaging; NAA: Neutron activation analysis; NP: Nanoparticle; PBCA: Poly(n-butyl
cyanoacrylate); RVG: Rabies virus glycoprotein; TEM: Transmission electron microscopy.
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Table 4. Brain nanoparticle distribution study claims, summary, critique, support for the claims and level of brain
or brain parenchymal entry. (cont.).
Claim Study summary Critique, support for claim and
level of demonstrated NP brain
entry
MRT (h) Ref.
‘Delivery of . . . NPs across the
blood–brain barrier’
CLSM images of mouse brain after oral administration of
60-nm PEG-coated, curcumin and piperine-coloaded
glyceryl monooleate NPs showed intracellular NPs
Neuronal intracellular NPs
supports delivery across the
BBB; 6
18(13) [50]
NP were ‘taken up into the brain
cells’
Rats with BBB opened by focused ultrasound received iv.
22-nm fluorescent probe-labeled low-density lipoprotein
NPs. Fluorescence microscopy images were interpreted as
showing punctate fluorescent staining within brain cell
cytosol
Brain parenchymal NP uptake
appears to be shown in the
presence of an opened BBB; 6
[46]
‘NP retention in brain tumors’ aIVIS-imaged whole and ex vivo mouse brain showed
accumulation in glioma after iv. 33–36-nm
fluorescent-labeled, penta-amino acid- or 2-cyano-6-amino
benzothiazole-, or both, coated gold NP injection.
bGlioma were excised for gold quantification by ICP–MS.
cTEM images showed intracellular densities
aWhole brain results using this
method show NP retention in
brain tumors; 1.
bICP–MS NP component in bulk
brain shows brain component
retention; 1.
cTEM showed brain parenchymal
NP entry in tumor cells; 6
[125]
‘[Quetiapine fumurate]-NP (IV)
may have crossed BBB by
opening tight junctions’
Brains removed from rats were homogenized and
quetiapine quantified by HPLC after iv. injection of
131-nm quetiapine fumarate-loaded chitosan NPs
HPLC results of NP component in
bulk brain do not verify BBB
crossing; 1
1.5(1.4) [126]
‘Successfully overcame the in vivo
BBB and BBTB delivery barriers’
aEx vivo brain and dissected tumors from mice with brain
tumors were fluorescent imaged 4 h after iv. injection of
fluorescent dye-loaded cyclic peptide-containing
approximately 100-nm liposomes.
bFluorescent images of brain with fluorescent-stained
microvessels show fluorescence from NPs separate from
microvessels
aWhole brain and tumor
fluorescence does not
demonstrate delivery across the
BBB or BBTB; 1.
bSpots of NP fluorescent dye
distinct from blood vessels
suggest NP distribution outside
of brain vasculature; 5
[127]
‘Ex vivo CT imaging and analysis
indicated that INS-GNPs
transported across the BBB’
aIn vivo and ex vivo CT mouse brain imaging was
conducted after iv. 20-nm insulin-coated, PEG-layered,
gold NP administration.
bFlame AAS of gold from digested brain was determined
aWhole brain CT images do not
verify transport across the BBB; 1.
bAAS results of NP component in
bulk brain do not verify transport
across the BBB; 1
15(18) [128]
‘Brain microvessel endothelial
cell targeting’
Brains of mice were perfused and prepared for
immunohistochemistry and fluorescence imaging after 2
iv. injections 1 h apart of 50-nm transferrin
antibody-conjugated mesoporous silica NPs. BMECs were
labeled with biotinylated potato lectin detected by
fluorescent-labeled streptavidin. One hour after the
second injection NPs were associated with the BMECs.
There was no evidence brain parenchymal penetration
NP brain microvessel targeting
was demonstrated; 3
[129]
‘Enhanced drug transport across
BBB’
aIron was determined by AAS in mouse organs after iv.
injection of 80-nm dextran-spermine
superparamagnetic-core NPs and 96-nm transferrin-coated
NPs
bTissues were stained with Prussian blue to visualize iron
localization
aAAS results of NP component in
bulk brain do not verify transport
across the BBB; 1
bResolution not sufficient to
confirm iron transport across the
BBB; 1
Increased from h
24 to 168 after
injection
[130]
‘To further confirm the
translocation of CLS-PEG NPs
across the BBB’
‘C6 to pass through the
blood–brain barrier’
aRat brains were analyzed by fluorescence analysis after iv.
injection of 176-nm coumarin-6-labeled
cholesterol-containing PBCA NPs and 185-nm particles also
containing PEG.
bBrains from perfused rats were viewed using CLSM that
showed uniform extracellular fluorescence
aFluorescence results do not
confirm BBB translocation; 1.
bNP component in brain
extracellular space supports claim
of its passage through the BBB; 5
2.2 and 2.3(3.4
and 5.5)
[52]
Mean residence time from studies that reported brain and blood (in parentheses) levels at multiple times after dosing. Study multiple end points are designated by a, b, c before
the study summary and critique. The level of demonstrated nanoparticle brain entry is from the classification described in Table 3. The numbers after the sentences in column
3 refer to the level of demonstrated NP brain entry.
AAS: Atomic absorption spectroscopy; BBB: Blood–brain barrier; BBTB: Blood-brain tumor barrier; BMEC: Brain microvascular endothelial cell; BSA: Bovine serum albumin; CLSM:
Confocal laser scanning microscopy; EDS: Energy dispersive x-ray spectroscopy; EELS: Electron energy loss spectroscopy; FITC: Fluorescein isothiocyanate; ICP–MS: Inductively
coupled plasma–mass spectrometry; ICP–OES: Inductively coupled plasma–optical emission spectroscopy; INAA: Instrumental neutron activation analysis; ip.: Intraperitoneal; iv.:
Intravenous; IVIS: In vivo imaging system; MRT: Mean residence time; MSI: Mass spectrometry imaging; NAA: Neutron activation analysis; NP: Nanoparticle; PBCA: Poly(n-butyl
cyanoacrylate); RVG: Rabies virus glycoprotein; TEM: Transmission electron microscopy.
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Table 4. Brain nanoparticle distribution study claims, summary, critique, support for the claims and level of brain
or brain parenchymal entry. (cont.).
Claim Study summary Critique, support for claim and
level of demonstrated NP brain
entry
MRT (h) Ref.
‘The NPs crossed the BBB and
entered the brainparenchyma’
aGold in brains from perfused rats was determined by
INAA after iv. injection of
rhodamine-PEG-angiopep-2-labeled gold nanorods.
bBrain from a rat was fluorescent imaged after iv. injection
of rhodamine-PEG-angiopep-2-labeled gold nanorods.
cTEM of hippocampus of a perfused rat after iv. injection
of PEG-angiopep-2-labeled gold nanorods demonstrated
intracellular electron dense spots
aINAA results of NP component
in bulk brain does not
demonstrate distribution across
the BBB; 1.
bFluorescence results do not
confirm BBB translocation; 1.
cNP seen in brain parenchyma; 6,
assuming the spots were gold
nanorods
[131]
Brain delivery Brains from mice were homogenized for LC/MS RU
determination after iv. injection of marigold flower
extract (RU)-, polysorbate-80-containing lipid polymer
hybrid PLGA NPs
LC/MS results of NP component
support bulk brain delivery; 1
2.5(1.2) [132]
‘Uptake by neuronal cells and
appreciable crossing of
blood–brain barrier’
Brains from rats were homogenized, solvent extracted and
dimethyl fumarate determined by HPLC after oral
administration of dimethyl fumarate-containing solid lipid
NPs
HPLC results of NP component in
bulk brain do not verify neuronal
cell uptake or BBB crossing; 1
5.7(4.7) [133]
Lamotrigine brain uptake Lamotrigine was determined by HPLC in homogenized
brain after iv. injection of 125-nm lamotrigine-loaded
poly-ε-(D,L-lactide-co-caprolactone) NPs
HPLC results of NP component
show bulk brain uptake; 1
[134]
‘[DNA-coated gold NPs] can be
successfully delivered to specific
brain locations across the BBB in
mice using focused ultrasound’
Mice were iv. injected with 6–14-nm fluorescent-labeled
DNA-coated gold NPs after unilateral microbubble
injection and before ultrasound to open the BBB. The
effected hemisphere showed more NPs (bright-field and
fluorescence microscopy) than the contralateral
hemisphere
Resolution was not sufficient to
verify delivery across the BBB; 1
[135]
‘This strategy increased NP
translocation into brain
parenchyma’
CLSM of brain, stained for GFAP to localize astrocyte foot
processes, from mice iv. injected with 180-nm
ApoE4-coated, fluorescent dye-labeled, lipid,
polysorbate-80 NPs showed some fluorescence from the
NPs not surrounded by fluorescence from GFAP
Fluorescence from the NP label
appears to be in brain
parenchyma; 5
[25]
‘Gamma scintigraphicimages
showed . . . the radiolabeled
formulations successfully crossed
BBB’
aWhole rat gamma scintigraphy was conducted after iv.
injection of 24-nm AZT-containing 99mTc-labeled
nanoliposomes.
bAZT was determined by HPLC in homogenized brain of in
situ blood-perfused rats after iv. injection of 24 nm
AZT-containing 99mTc-labeled nanoliposomes
aWhole rat radioactivity does not
verify brain entry or BBB crossing.
bHPLC results of NP component
in bulk brain do not verify BBB
crossing 2
6.2(8.8) [136]
‘Blood–brain barrier permeability
of the NPs was successfully
demonstrated by the
incorporation of fluorescent dye,
Rhodamine B in the NPs’
Brain from rats was homogenized, solvent extracted and
Rhodamine B determined by HPLC after ip. injection of
300–400-nm saxagliptin-loaded chitosan-L-valine-based
NPs
HPLC results of NP component in
bulk brain do not verify BBB
permeability; 1
[137]
Brain accumulation of
curcumin-loaded NPs
Fluorescence in homogenized brains from perfused rats
was determined byHPLC after iv. injection of 46-nm
6-coumarin-loaded oleic acid-conjugated
PEG-poly(ε-caprolactone) NPs
HPLC results of NP component
show bulk brain delivery; 2
[138]
‘After intravenous
administration, fluorescent [solid
lipid NPs] were detected in brain
parenchyma outside the vascular
bed, confirming their ability to
overcome the BBB’
Epi-fluorescence microscopy of rat brain 24 h after iv.
injection of 278-nm FITC and Brij 78-containing solid lipid
NPs showed spherical fluorescence not associated with an
endothelial marker
Spherical fluorescence in absence
of blood vessel marker
fluorescence suggests NP brain
parenchymal entry; 5
[139]
Mean residence time from studies that reported brain and blood (in parentheses) levels at multiple times after dosing. Study multiple end points are designated by a, b, c before
the study summary and critique. The level of demonstrated nanoparticle brain entry is from the classification described in Table 3. The numbers after the sentences in column
3 refer to the level of demonstrated NP brain entry.
AAS: Atomic absorption spectroscopy; BBB: Blood–brain barrier; BBTB: Blood-brain tumor barrier; BMEC: Brain microvascular endothelial cell; BSA: Bovine serum albumin; CLSM:
Confocal laser scanning microscopy; EDS: Energy dispersive x-ray spectroscopy; EELS: Electron energy loss spectroscopy; FITC: Fluorescein isothiocyanate; ICP–MS: Inductively
coupled plasma–mass spectrometry; ICP–OES: Inductively coupled plasma–optical emission spectroscopy; INAA: Instrumental neutron activation analysis; ip.: Intraperitoneal; iv.:
Intravenous; IVIS: In vivo imaging system; MRT: Mean residence time; MSI: Mass spectrometry imaging; NAA: Neutron activation analysis; NP: Nanoparticle; PBCA: Poly(n-butyl
cyanoacrylate); RVG: Rabies virus glycoprotein; TEM: Transmission electron microscopy.
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Table 4. Brain nanoparticle distribution study claims, summary, critique, support for the claims and level of brain
or brain parenchymal entry. (cont.).
Claim Study summary Critique, support for claim and
level of demonstrated NP brain
entry
MRT (h) Ref.
‘Ex vivo imaging and
semiquantitative assay of the
brains demonstrated the brain
penetrating behavior of . . . NPs’
aWhole mice were multispectral and ex vivo brain CLSM
imaged after iv. injection of 148-nm menthol BSA NPs.
bCLSM and TEM images were obtained of the pineal gland
(which lacks a BBB) of rats after iv. 148-nm menthol BSA
silver NP injection
aWhole-body multispectral and
CLSM imaging show bulk brain
delivery; 1.
bTEM shows one electron dense
spot. Its chemical composition
was not reported; 6, assuming Ag
in the spot
[53]
Bioavailability of quercetin in the
brain
Brains from rats were homogenized, proteins precipitated
and quercetin determined by HPLC after oral feeding of
30–50-nm quercetin-coated superparamagnetic iron oxide
NPs
HPLC results of NP component
show bulk brain delivery; 1
[140]
Brain distribution/delivery Brains from rats were homogenized, proteins precipitated
and rivastigmine determined by HPLC after iv. injection of
145-nm rivastigmine-loaded mesoporous silica NPs
HPLC results of NP component
show bulk brain delivery; 1
6.5 [141]
Penetration of NPs into brain
parenchyma
Three adjacent sections from isolated guinea pig brains
were assessed bysilver-enhanced brightfield microscopy,
CLSM and TEM after arterial perfusionfor 120 min of
approximately 8 nm fluorescent-labeled
mercaptoundecylsulfonic acid/octanethiol coated
gold/iron core NPs followed by 30-min washout perfusion
CLSM indicates fluorescence
surrounding cell nuclei. Optical
microscopy shows silver stain
surrounding blood vessels. TEM
shows electron dense particles on
the luminal wall of BMECs and
inside brain cells; 6
[22]
NPs ‘passed the BBB, and entered
the cytoplasm of vascular
endothelial cells, as depicted by
the biodistribution studies, flow
cytometry analysis and
subcellular TEM micrographs.’
aBrains from perfused mice were homogenized and cells
analyzed by flow cytometry 1 h after ip. injection of
fluorescent-labeled glucose- or PEG-glucose-coated silica
NPs.
bBrains from perfused mice were CLSM imaged 1 h after
ip. injection of fluorescent-labeled glucose- or
PEG-glucose-coated silica NPs.
cBrains harvested from mice were TEM imaged 1 h after
ip. injection of fluorescent-labeled PEG-glucose-coated
silica NPs
aFlow cytometry does not reveal
cell type or NP localization in, vs
on, the cell; 2.
bCLSM images do not verify brain
parenchymal localization; 2.
cTEM shows electron densities,
perhaps in neurons; 6
[54]
‘NP formulation increased BBB
transport . . . in vivo’
aWhole mouse fluorescence imaging was conducted from
0.25 to 24 h after intranasal dosing of indocyanine green
containing transferrin or RVG-coated BSA NPs.
bOxytocin in CSF was determined by enzyme-linked
immunosorbent assay after intranasal dosing of
oxytocin-containing RVG-coated BSA NPs
aWhole body bioimaging does
not verify BBB transport; 1.
bNP component in CSF does not
demonstrate brain uptake
7.4 [82]
‘Enhanced delivery of
[doxorubicin] across the BBB’
HPLC of dialysates from microdialysis of rat hippocampus
after intranasal dosing of 92-nm polysaccharide NP
containing doxorubicin showed doxorubicin concentration
peak at 30 min
Peak doxorubicin concentration
this soon cannot be due to nose
to hippocampus neuronal
transport. It would be
distribution across the BBB. NP
component does not
demonstrate brain NP uptake; 1
4.2 [77]
‘[NP] rapidly and effectively
delivered drugs to the brain via
the nose-to-brain pathway’
Mouse brain was IVIS imaged ex vivo and MRI imaged
after intranasal dosing of 110- or 143-nm fluorescent and
gadolinium-labeled cholera toxin or BSA NP
Whole brain results using these
methods show fluorescence and
gadolinium in the brain; 1
11.6 [142]
NP delivery to the brain Ex vivo brain was IVIS imaged after iv. injection of
fluorescent-labeled, microbubble complexed, albumin NPs
and ultrasound to brain tumor bearing mice
Whole brain results using this
method show fluorescence in the
brain; 1
[143]
Mean residence time from studies that reported brain and blood (in parentheses) levels at multiple times after dosing. Study multiple end points are designated by a, b, c before
the study summary and critique. The level of demonstrated nanoparticle brain entry is from the classification described in Table 3. The numbers after the sentences in column
3 refer to the level of demonstrated NP brain entry.
AAS: Atomic absorption spectroscopy; BBB: Blood–brain barrier; BBTB: Blood-brain tumor barrier; BMEC: Brain microvascular endothelial cell; BSA: Bovine serum albumin; CLSM:
Confocal laser scanning microscopy; EDS: Energy dispersive x-ray spectroscopy; EELS: Electron energy loss spectroscopy; FITC: Fluorescein isothiocyanate; ICP–MS: Inductively
coupled plasma–mass spectrometry; ICP–OES: Inductively coupled plasma–optical emission spectroscopy; INAA: Instrumental neutron activation analysis; ip.: Intraperitoneal; iv.:
Intravenous; IVIS: In vivo imaging system; MRT: Mean residence time; MSI: Mass spectrometry imaging; NAA: Neutron activation analysis; NP: Nanoparticle; PBCA: Poly(n-butyl
cyanoacrylate); RVG: Rabies virus glycoprotein; TEM: Transmission electron microscopy.
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Table 4. Brain nanoparticle distribution study claims, summary, critique, support for the claims and level of brain
or brain parenchymal entry. (cont.).
Claim Study summary Critique, support for claim and
level of demonstrated NP brain
entry
MRT (h) Ref.
NP ‘transport across the BBB
after intravenous administration’
CLSM images are claimed to show 140–200-nm
phosphatidic and sialic acid,
5-hydroxytryptamine-moduline modified PLGA NPs in the
hippocampus of rats after their iv. injection
No fluorescence attributed to the
NPs can be seen
[55]
BBB penetration and NP
distribution into brain
parenchyma
Epifluorescence was determined in brain regions that did
not contain vasculature after iv. injection of 4-nm
Angiopep-2, transferrin receptor ligand, endosome escape
unit, fluorescent marker containing malic acid NPs in mice
whose cerebrovascular was stained. The results were
interpreted to indicate that the NPs traversed the BBB and
approximately 40% of plasma fluorescence was in the
parenchyma with the highest concentration proximal to
the vasculature
The methods suggest the
fluorescent component of the NP
entered brain parenchyma; 5
[144]
‘[NP] crossing intact BBB was . . .
demonstrated in healthy mice’
Confocal microscopy of mouse brain after iv. injection of
126-nm doxorubicin, mitomycin C and internalizing
peptide-labeled terpolymer-lipid hybrid NP after iv.
injection of Texas-red-dextran to visualize blood vessels
showed particulate doxorubicin fluorescence not
associated with blood vessels
Punctate fluorescence attributed
to doxorubicin not associated
with blood vessels suggests brain
parenchymal NP entry; 6
[145]
Mean residence time from studies that reported brain and blood (in parentheses) levels at multiple times after dosing. Study multiple end points are designated by a, b, c before
the study summary and critique. The level of demonstrated nanoparticle brain entry is from the classification described in Table 3. The numbers after the sentences in column
3 refer to the level of demonstrated NP brain entry.
AAS: Atomic absorption spectroscopy; BBB: Blood–brain barrier; BBTB: Blood-brain tumor barrier; BMEC: Brain microvascular endothelial cell; BSA: Bovine serum albumin; CLSM:
Confocal laser scanning microscopy; EDS: Energy dispersive x-ray spectroscopy; EELS: Electron energy loss spectroscopy; FITC: Fluorescein isothiocyanate; ICP–MS: Inductively
coupled plasma–mass spectrometry; ICP–OES: Inductively coupled plasma–optical emission spectroscopy; INAA: Instrumental neutron activation analysis; ip.: Intraperitoneal; iv.:
Intravenous; IVIS: In vivo imaging system; MRT: Mean residence time; MSI: Mass spectrometry imaging; NAA: Neutron activation analysis; NP: Nanoparticle; PBCA: Poly(n-butyl
cyanoacrylate); RVG: Rabies virus glycoprotein; TEM: Transmission electron microscopy.
dependent, increasing from less than 96 h after 60 μg to approximately 480 h after 1600 μg [81], suggesting the
quantity of NPs in brain parenchyma influence their duration of persistence in that compartment.
Some studies reported the brain level of the NP or its components at multiple times after its peripheral
administration. Some studies also reported blood and/or peripheral organ levels. The reported values are shown
in Supplementary Figure 1. To be able to visually compare the rates of NP/component increase or decrease over
time given the wide range of levels and timecourses among the studies, the results were normalized to the dose for
CED studies or first reported value for other studies and shown as double log figures. It is expected that NPs that
entered brain parenchyma would persist longer in the brain than NPs that did not cross the BBB, and longer than
in the blood. Most reports of brain NP or component determination over time did not have many values (range
for the non-CED and non-microdialysis studies: 2–16, median: 5) discouraging rigorous pharmacokinetic analysis
or estimate of NP residence to infinity. Noncompartmental mean residence time (MRT) to the last sample was
determined using Phoenix 8.1 WinNonLin. The MRT of NPs or their components after peripheral or intranasal
administration is generally less than after CED, suggesting less than 100% of the NPs or components entered brain
parenchyma. Good agreement was obtained between the MRT results and author reported half-lives for the same
datasets (Tables 1 & 4). The MRT was similarly calculated for NP, or its component, in blood from the studies that
determined them at multiple times after NP administration. The results are shown in parentheses in Table 4. The
timecourse and MRTs for the NP or its component in the brain, blood and peripheral organs were often similar
(Supplementary Figure 1 & Table 4). This could be due to most or all of the NP/component in the brain residing
in blood within the brain or adhering to the luminal wall of BMECs and being cleared from brain at the same
rate as blood clearance from peripheral circulation. Exceptions were seen in two reports where the brain MRT
was considerably longer than blood MRT [17,58], suggesting NP distribution beyond the vascular compartment.
However, evidence of brain parenchymal entry was not provided.
Studies classified according to the criteria in Table 3 as demonstrating brain parenchymal entry (levels 5 and 6)
that reported brain NP or component levels at multiple times are shown in Supplementary Figure 1D and E. Brain
levels often increased over time or decreased more slowly than in studies classified as not showing brain parenchymal
entry. Brain levels often decreased more slowly than blood levels in studies shown in Supplementary Figure 1D
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and E than B or C. There is some concordance between the classification levels and NP/component timecourse in
the brain, suggesting the rate of NP/component clearance from the brain reflects the absence or presence of brain
parenchymal entry.
The evidence of NP parenchymal entry may not be from the same measure as that providing the brain
timecourse (e.g., TEM showing NP in brain cells, whereas NP/marker residence determined by HPLC). When NP
or component was determined by radioactivity, neutron activation analysis, IVIS imaging, fluorescence, HPLC,
atomic absorption spectroscopy, inductively coupled plasma–optical emission spectroscopy, inductively coupled
plasma–mass spectrometry or LC–MS, it could be that only a fraction was in brain parenchyma. A risk of concluding
NP brain entry or brain parenchymal entry from a component of the NP, such as an incorporated fluorescent dye
or a metal component of a metal- or metal oxide-containing NP, is that the dye or metal might be released and its
distribution does not represent the NP. For example, it was concluded that dye clearance from the brain in 24 h was
‘most likely due to degradation of the dye itself rather than actual clearance of the NPs from the brain’ [82]. Similarly,
metal analysis by neutron activation analysis, atomic absorption spectroscopy, inductively coupled plasma–optical
emission spectroscopy or inductively coupled plasma–mass spectrometry may be informing about released ion,
particularly from readily soluble NPs such as those containing copper, silver and zinc.
In contrast, the results of many studies which did not demonstrate NP distribution in brain parenchyma showed
more rapid clearance of brain-associated NPs (Table 4 & Supplementary Figure 1). Many studies did not remove
blood from the brain. The decline of NPs within a few hours in the brain, at a rate similar to its decline in blood,
and more rapidly than the decline from peripheral organs, may be due to lack of brain parenchymal entry. Such
results suggest that only some, or none, of the NPs crossed the BBB. The NPs may have adhered to the luminal wall
of brain vasculature or localized in cellular or membrane components of the BBB, and subsequently distributed
away from these sites into blood circulating through the brain. In studies that did not use sufficient methods to
demonstrate NP brain parenchymal entry, the NPs may indeed have crossed the BBB. However, the methods do
not verify that. If procedures are used to rule out the contribution of NPs in blood and adherence to BMECs, NP
persistence in the brain may indicate successful distribution across the BBB.
Conclusion
The BBB and BCSFB provide a significant challenge to deliver substances into the brain to access neural, glial
and cancer cells. Verification that the substance has entered into the compartment that houses these cells (brain
parenchyma) is not trivial. Experimental results are sometimes overinterpreted to suggest successful delivery of
substances that might directly act on cells in the brain when verification of brain parenchymal entry is lacking.
An understanding of the anatomy and location of the barriers (BBB and BCSFB) to brain parenchymal entry
helps one interpret if a substance has entered brain parenchyma. Visual and procedural methods have been used to
verify brain parenchymal entry. In this article, methods have been classified as to the level of verification of brain
parenchymal entry and then critically applied to studies. The BBB can be bypassed by direct substance introduction
into the brain by CED that often results in prolonged residence of the substance in the brain. It is suggested that
prolonged substance residence in the brain after its peripheral (e.g., iv.) administration suggests brain parenchymal
entry. It is hoped that this guide will help researchers and reviewers be more precise in their demonstration and
interpretation of substance distribution in the brain.
Future perspective
As the study of NP biological interaction matures, there is greater understanding of how to critically assess NP
effects and their distribution. If the criteria and methods that demonstrate bulk brain and brain parenchymal
entry proposed herein are employed by researchers and reviewers, there will be more precise reporting of brain
NP distribution. More realistic result interpretation will enable more realistic clinical benefit expectation. This will
enhance the credibility of this endeavor and help investigators engage in best practice research.
Supplementary data
To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/sup
pl/10.2217/nnm-2019-0169
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Executive summary
• The anatomy and function of the blood–brain (BBB) and blood-cerebrospinal fluid barriers are reviewed.
• Exposure routes to bypass the BBB (convection-enhanced delivery and uptake from the nasal cavity by cranial
nerves) are described.
• Visual and procedural methods to determine nanoparticle (NP) brain and brain parenchymal entry are presented.
• Criteria are proposed to classify levels of experimental result evidence that demonstrate NP bulk brain or brain
parenchymal entry.
• Studies of NP brain entry or distribution across the BBB are summarized, critiqued and evaluated using the
classification levels to interpret if the study shows NP bulk brain or brain parenchymal entry.
• NP or component persistence in the brain after systemic or intranasal administration compared with blood and
peripheral organs and direct infusion by convection-enhanced delivery into the brain are compared with
interpret support for NP distribution beyond the brain vasculature, into brain parenchyma.
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